VICTORIA, BC, Sept. 11,
2023 /CNW/ - Eupraxia Pharmaceuticals Inc.
("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage
biotechnology company with an innovative drug delivery technology,
today announced that it will present at the H.C. Wainwright
25th Annual Global Investment Conference being held in
New York, NY from September 11 to 13, 2023.
The Company's on-demand presentation is now available. Eupraxia
invites all interested parties to view the presentation by clicking
on the following link:
A webcast of the presentation will also be available on the
Events and Presentations page of the Company's website here.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient
benefit and has developed technology that delivers targeted,
long-lasting activity with fewer side effects.
Eupraxia's lead product candidate, EP-104IAR, recently completed
a Phase 2b clinical trial for the
treatment of pain due to osteoarthritis of the knee. EP-104IAR met
its primary endpoint and three of the four secondary endpoints. The
EP-104 platform has expanded into gastrointestinal disease and has
dosed patients in a Phase 1b/2a
program to treat eosinophilic esophagitis. Eupraxia is also
developing a pipeline of later- and earlier-stage long-acting
formulations. Potential pipeline indications include candidates for
both other inflammatory joint indications and oncology, each
designed to improve on the activity and tolerability of currently
approved drugs. For further details about Eupraxia, please visit
the Company's website at: www.eupraxiapharma.com.
SOURCE Eupraxia Pharmaceuticals Inc.